Skip to main content
Signal8
Launch Terminal

Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Dermata Therapeutics, Inc. logo

Dermata Therapeutics, Inc.

NASDAQ:DRMAHealthcare
-7.86%$0.7750
AH$0.7899+1.92%vs close
Mkt Cap$3.84M
Float3.02M
O/S4.96M
Vol
$ Vol
RVOL
Inst Own2.4%
Earnings
Dilution
Dermata Therapeutics, Inc. logoNASDAQ:DRMA$0.7750-7.86%
Phase Distribution
6 lead-sponsored trials·0 active·5 completed
Phase 25
Phase 31
Status Overview
Completed5
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Completed

    DMT310-009 Topical in the Treatment of Acne Vulgaris

    DMT310, Placebo

    Acne Vulgaris

    Enrollment
    520
    Start
    Dec 2023
    Primary Completion
    Mar 2025
    Completion
    Apr 2025
    NCT06090721
  • Phase 2
    Completed

    DMT210 Topical Gel in the Treatment of Atopic Dermatitis

    DMT210 Topical Gel, Vehicle Control

    Atopic Dermatitis

    Enrollment
    19
    Start
    Oct 2016
    Primary Completion
    Jul 2017
    Completion
    Jul 2017
    NCT02949960
  • Phase 2
    Completed

    DMT210 Topical Gel in the Treatment of Acne Rosacea

    DMT210 Topical Gel 5%

    Acne Rosacea

    Enrollment
    107
    Start
    Jan 2017
    Primary Completion
    Aug 2017
    Completion
    Aug 2017
    NCT03003104
  • Phase 2
    Completed

    DMT310-001 Topical in the Treatment of Acne Vulgaris

    DMT310, Hydrogen Peroxide

    Acne Vulgaris

    Enrollment
    121
    Start
    May 2018
    Primary Completion
    Dec 2018
    Completion
    Jan 2019
    NCT03536637
  • Phase 2
    Completed

    DMT310-003 Topical in the Treatment of Acne Vulgaris

    DMT310, Placebo

    Acne Vulgaris

    Enrollment
    181
    Start
    Oct 2019
    Primary Completion
    May 2020
    Completion
    May 2020
    NCT04106778
  • Phase 2
    Unknown status

    DMT310-005 Topical in the Treatment of Acne Rosacea

    Topical Powder, Placebo Topical Powder

    Acne Rosacea

    Enrollment
    180
    Start
    Nov 2021
    Primary Completion
    Dec 2022est.
    Completion
    Dec 2022est.
    NCT05108025
Search ClinicalTrials.gov for “Dermata Therapeutics”